(+)-JQ1 PA

(+)-JQ1 PA is a derivative of the Bromodomain and extra-terminal (BET) inhibitor JQ1, with an IC50 of 10.4 nM.

Signaling Pathways >> Epigenetics >> Epigenetic Reader Domain

Research Areas >> Cancer

10.4 nM (BET)[1].

(+)-JQ1 PA is a derivative of JQ1, which is the inhibitor of BET. The IC50 of (+)-JQ1 PA for BET is 10.4 nM, and the IC50 of JQ1 is 14.3 nM in MV4;11 cells[1].

Proliferation of MV4;11 cells after 72 hours of treatment, comparing JQ1 versus JQ1-PA are tested. Cell cycle profile of MV4;11 cells after 48 hours of treatment with DMSO, JQ1, JQ1-PA, or JQ1-TCO (all compounds used at 500 nM) are tested[1].

[1]. Tyler DS, et al. Click chemistry enables preclinical evaluation of targeted epigenetic therapies. Science. 2017 Jun 30;356(6345):1397-1401.

(+)-JQ1 | GSK126 | Tazemetostat (EPZ-6438) | Birabresib (OTX015) | A 485 | Curcumin | ARV-771 | ARV-825 | I-BET762 | BI 2536 | GSK343 | C646 | 3-Deazaneplanocin A (hydrochloride) | I-BET151 | 666-15